New drug combo aims to control rare blood cancer

NCT ID NCT02737046

Completed Disease control Sponsor: University of Miami Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tested a combination of belinostat (a cancer drug) and zidovudine (AZT, an HIV drug) as consolidation therapy for adult T-cell leukemia-lymphoma (ATLL), a rare and aggressive blood cancer. Fifteen participants received the drugs to see if it could eliminate cancer cells from the blood and improve disease control. The study also monitored side effects and overall response rates.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: belinostat and zidovudine (AZT)
What this could lead to: If it works, this could point toward a more effective consolidation treatment for adult T-cell leukemia-lymphoma, potentially improving long-term control of the disease.
What could go wrong: This is a small, early-phase trial with only 15 participants, so results may not apply to all patients. The combination may cause serious side effects, and it is not a cure—patients will need ongoing maintenance therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADULT T-CELL LEUKEMIA/LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adult T-cell leukemia/lymphoma Leukemia-Lymphoma, Adult T-Cell

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADULT T-CELL LEUKEMIA/LYMPHOMA ATLL

Contacts and locations

Locations

University of Miami

Miami, Florida, 33136, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.